# ZBIO catalysts: Zenas BioPharma, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/zbio/catalysts

> Zenas BioPharma, Inc. (ZBIO) has 8 upcoming catalysts. The next is the ZB022 interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ZBIO?

Zenas BioPharma, Inc. (ZBIO) has 8 upcoming catalysts. The next is the ZB022 interim data readout, 2027. Press release filed with the SEC (EX-99): "Subject to the results of IND-enabling studies, Zenas expects to submit an IND application for ZB022, and if cleared, initiate a Phase 1 clinical study in 2026, with the potential for initial data in 2027." [Calendar and source filings](https://sec-api.dev/companies/zbio/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-25-097663, https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm (retrieved 2026-11-12). Last confirmed 2026-03-16. Cite: https://sec-api.dev/companies/zbio/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Zenas BioPharma, Inc. |
| Ticker | ZBIO (Nasdaq) |
| SEC CIK | 1953926 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/zbio |

## Cash runway

Cash $647.1M as of 2026-09-30; quarterly burn $58.0M; about 33.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-123040).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 12, 2024 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_ex99-1.htm)) |
| February 5, 2025 | [INDIGO (vorasidenib) earnings report](https://sec-api.dev/pdufa/vorasidenib) | ZBIO |  | completed | "Forward-looking statements include, but are not limited to, statements concerning Zenas's plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting INDIGO trial topline results, the 12-week primary endpoint data for the MoonStone trial and the anticipated timing of completing enrollment and reporting topline results for the SunStone trial; its growth strategy; the Company's preliminary unaudited cash, cash equivalents and short-term investments as of December 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/tm255498d1_ex99-1.htm)) |
| May 15, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm)) |
| August 12, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm)) |
| August 28, 2025 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Relapsing Multiple Sclerosis | completed | "NCT06564311 (A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564311)) |
| late 2025 | [INDIGO (vorasidenib) topline data readout](https://sec-api.dev/pdufa/vorasidenib) | ZBIO |  | scheduled | "Target enrollment of the INDIGO trial concluded in November 2024, and Zenas expects to report topline results around year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-1.htm)) |
| Q4 2025 | [Obexelimab topline data readout](https://sec-api.dev/pdufa/obexelimab) | ZBIO |  | scheduled | "The Company expects to report topline results from this trial, including the 12-week primary endpoint results, early in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm)) |
| November 12, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925109737/tm2530850d1_ex99-1.htm)) |
| November 13, 2025 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | IgG4 Related Disease | completed | "NCT05662241 (A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05662241)) |
| 2026 | [ZB021 trial start](https://sec-api.dev/pdufa/zb021) | ZBIO |  | scheduled | "Subject to the results of Investigational New Drug ("IND")-enabling studies, Zenas expects to submit an IND application for ZB021, and if cleared, initiate a Phase 1 clinical study in 2026, with the potential for initial data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm)) |
| Q1 2026 | [Orelabrutinib trial start](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "The Company also expects to initiate a global Phase 3 trial of orelabrutinib in patients with Secondary Progressive Multiple Sclerosis ("SPMS") in the first quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_8k.htm)) |
| Mar 2026 | [Orelabrutinib trial start](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | non-active secondary progressive multiple sclerosis | completed | "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis, with a primary endpoint of time to onset of 24-week CDP." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm)) |
| March 16, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926027961/tm268878d1_ex99-1.htm)) |
| Q2 2026 | [Obexelimab NDA/BLA submission](https://sec-api.dev/pdufa/obexelimab) | ZBIO | IgG4-RD | scheduled | "Following the positive Phase 3 INDIGO results, the Company anticipates submitting a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for obexelimab in IgG4-RD in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1953926/000110465926000402/tm261774d1_8k.htm)) |
| mid-2026 | [Obexelimab topline data readout](https://sec-api.dev/pdufa/obexelimab) | ZBIO |  | scheduled | "around year-end 2025, and we expect to report topline results from the SunStone trial in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm)) |
| May 2026 | [Obexelimab NDA/BLA submission](https://sec-api.dev/pdufa/obexelimab) | ZBIO | IgG4-RD in May 2026 | completed | "Based on these results, we submitted the obexelimab Biologics License Application ("BLA") to the FDA for the treatment of IgG4-RD in May 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm)) |
| May 11, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm)) |
| June 2026 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Warm Autoimmune Hemolytic Anemia | delayed | "NCT05786573 (A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-30 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05786573)) |
| Aug 2026 | [Obexelimab NDA/BLA acceptance](https://sec-api.dev/pdufa/obexelimab) | ZBIO |  | completed | "In August 2026, the FDA accepted the Company's BLA and assigned a Prescription Drug User Fee Act ("PDUFA") target date of May 27, 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm)) |
| August 12, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm)) |
| September 2026 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Systemic Lupus Erythematosus | delayed | "NCT06559163 (A Study of Obexelimab in Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559163)) |
| Q4 2026 | [Obexelimab topline data readout](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Systemic Lupus Erythematosus | scheduled | "Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_ex99-1.htm)) |
| Q4 2026 | [Zenas BioPharma, Inc. topline data readout](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | scheduled | "2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in the fourth quarter 2026: Zenas anticipates reporting topline results, including results from a biomarker subset from the Phase 2 SunStone trial in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| Q4 2026 | [Zenas BioPharma, Inc. topline data readout](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | scheduled | "2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026: Zenas anticipates reporting topline overall and biomarker population results in the fourth quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926095437/tm2622871d1_ex99-1.htm)) |
| Q4 2026 | [ZB021 interim data readout](https://sec-api.dev/pdufa/zb021) | ZBIO |  | scheduled | "- ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected fourth quarter 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| November 5, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| 2027 | [ZB022 interim data readout](https://sec-api.dev/pdufa/zb022) | ZBIO |  | scheduled | "Subject to the results of IND-enabling studies, Zenas expects to submit an IND application for ZB022, and if cleared, initiate a Phase 1 clinical study in 2026, with the potential for initial data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm)) |
| 2027 | [ZB021 interim data readout](https://sec-api.dev/pdufa/zb021) | ZBIO |  | scheduled | "Subject to the results of Investigational New Drug ("IND")-enabling studies, Zenas expects to submit an IND application for ZB021, and if cleared, initiate a Phase 1 clinical study in 2026, with the potential for initial data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm)) |
| 2027 | [ZB022 trial start](https://sec-api.dev/pdufa/zb022) | ZBIO |  | scheduled | "ZB022, an oral, brain-penetrant, TYK2-JH2 inhibitor o IND enabling studies ongoing: Zenas expects to initiate a Phase 1 clinical study in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| May 27, 2027 | [Obexelimab PDUFA date](https://sec-api.dev/pdufa/obexelimab) | ZBIO |  | scheduled | "PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926123035/tm2628936d1_ex99-1.htm)) |
| June 2030 | [Orelabrutinib primary completion](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Multiple Sclerosis (MS) Primary Progressive | scheduled | "NCT07067463 (A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07067463)) |
| Jun to Sep 2030 | [Orelabrutinib topline data readout](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Multiple Sclerosis (MS) Primary Progressive | scheduled | "NCT07067463 (A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07067463)) |
| June 2030 | [Orelabrutinib primary completion](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07299019)) |
| Jun to Sep 2030 | [Orelabrutinib topline data readout](https://sec-api.dev/pdufa/orelabrutinib) | ZBIO | Secondary Progressive Multiple Sclerosis | scheduled | "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07299019)) |

## Drugs

- [Obexelimab](https://sec-api.dev/pdufa/obexelimab): igg4-rd, igg4-rd in may 2026, igg4-rd in second quarter 2026 -, immunoglobulin g4-related disease, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis, Systemic Lupus Erythematosus
- [Orelabrutinib](https://sec-api.dev/pdufa/orelabrutinib): secondary progressive multiple sclerosis, non-active secondary progressive multiple sclerosis, non-active spms, secondary progressive ms, Multiple Sclerosis (MS) Primary Progressive
- [INDIGO (vorasidenib)](https://sec-api.dev/pdufa/vorasidenib): idh1- or idh2-mutant grade 2 astrocytoma or oligodendroglioma, idh1- or idh2-mutant grade 2 22 astrocytoma or oligodendroglioma, grade 2 astrocytoma or oligodendroglioma
- [ZB021](https://sec-api.dev/pdufa/zb021): 
- [ZB022](https://sec-api.dev/pdufa/zb022): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/zbio/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZBIO catalysts: Zenas BioPharma, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/zbio/catalysts

```bibtex
@misc{secapidev_companies_zbio_catalysts_20261116,
  title        = {ZBIO catalysts: Zenas BioPharma, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/zbio/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_zbio_catalysts_20261116","title":"ZBIO catalysts: Zenas BioPharma, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/zbio/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
